GRFPE Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.82 |
52 Week High | €10.76 |
52 Week Low | €5.86 |
Beta | 0.67 |
1 Month Change | 8.51% |
3 Month Change | n/a |
1 Year Change | -9.67% |
3 Year Change | -55.71% |
5 Year Change | -57.85% |
Change since IPO | -28.81% |
Recent News & Updates
Recent updates
Shareholder Returns
GRFPE | GB Biotechs | GB Market | |
---|---|---|---|
7D | 6.5% | 1.3% | 1.0% |
1Y | -9.7% | -19.3% | 6.7% |
Return vs Industry: GRFPE exceeded the UK Biotechs industry which returned -19.3% over the past year.
Return vs Market: GRFPE underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
GRFPE volatility | |
---|---|
GRFPE Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GRFPE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GRFPE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,744 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
GRFPE fundamental statistics | |
---|---|
Market cap | €6.00b |
Earnings (TTM) | €189.00m |
Revenue (TTM) | €6.66b |
35.8x
P/E Ratio1.0x
P/S RatioIs GRFPE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRFPE income statement (TTM) | |
---|---|
Revenue | €6.66b |
Cost of Revenue | €4.09b |
Gross Profit | €2.56b |
Other Expenses | €2.37b |
Earnings | €189.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | 0.28 |
Gross Margin | 38.51% |
Net Profit Margin | 2.84% |
Debt/Equity Ratio | 140.3% |
How did GRFPE perform over the long term?
See historical performance and comparison